GLP-1 RECEPTOR AGONISTS AND USE THEREOF Russian patent published in 2021 - IPC C07D401/14 C07D405/14 C07D413/14 C07D471/04 C07D487/04 A61K31/4427 A61K31/497 A61P3/00 

FIELD: organic chemistry.

SUBSTANCE: present invention refers to a compound of formula I

,

or its pharmaceutically acceptable salt. In formula I, each R¹ independently represents halogen, -CN, -C_1-3alkyl or -OC_1-3alkyl, where alkyl C_1-3alkyl and OC_1-3alkyl are substituted with 0–3 F atoms; m is 0, 1, 2 or 3; each R² independently represents F or Cl; p equals 0 or 1; each R³ independently represents F, -OH, -C_1-3alkyl or -C_3-4cycloalkyl or 2 R³ can be cyclised together to form -C_3-4spirocycloalkyl, wherein said -C_1-3alkyl and -C_3-4cycloalkyl can be substituted with 0–3 valence by F and 0–1 -OH; q equals 0, 1 or 2; Y is CH or N; R⁴ is -C_1-3alkyl, -C_0-3alkylene-C_3-6cycloalkyl, -C_0-3alkylene-R⁵ or C_1-3alkylene R⁶, where said alkyl can be substituted with 0–3 substitutes, independently selected from 0–3 atoms of F and 0–1 substituents selected from C_0-1alkylene OR^O, and where said cycloalkyl can be independently substituted with 0–2 substituents depending on valency of 0, independently selected from 0–2 atoms of F and 0–1 substituents selected from C_0-1alkylene OR^O; R⁵ is 4–6 membered heterocycloalkyl (where said heterocycloalkyl can contain 1 to 2 heteroatoms selected from O and/or N), wherein said heterocycloalkyl can be substituted with 0–2 substitutions independently selected from: 0–1 oxo (=O) and 0–2 substitutes independently selected from -C_1-3alkyl and -OC_1-3alkyl, wherein alkyl C_1-3alkyl and -OC_1-3alkyl can be substituted with 0–3 substitutes independently selected from: 0–1 -OR^O; R⁶ is 5–6 membered heteroaryl (where said heteroaryl can contain from 1 to 3 heteroatoms selected from O and/or N), where said heteroaryl can be substituted with 0–2 substitutions independently selected from: 0–2 halogens and 0–2-C_1-3alkyls, where alkyl can be substituted with 0–3 substitutes independently selected from: 0–1 -OR^O; each R^O independently represents H or -C_1-3alkyl; Z¹ is CH or N; Z² and Z³ each independently represent -CR^Z or N, with the proviso that when Z¹ or Z³ is N, Z² is -CR^Z; and each R^Z independently represents H, F, Cl or -CH₃. Pharmaceutical composition is also presented.

EFFECT: disclosed are novel organic compounds which can be used as GLP-1R agonists.

23 cl, 9 tbl, 21 ex